Cowen Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Market Perform

Cowen downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Outperform to Market Perform.

Analyst Eric Schmidt commented, "Sunesis announced that recent FDA discussions were not supportive of an NDA filing for vosaroxin. The company will proceed with an MAA filing in r/r AML patients >60 years old. While we think EU approval is likely, resource constraints are likely to make it very difficult for Sunesis to monetize the residual value in vosaroxin or its early stage pipeline. Hence we are moving to the sidelines."

For an analyst ratings summary and ratings history on Sunesis Pharmaceuticals Inc. click here. For more ratings news on Sunesis Pharmaceuticals Inc. click here.

Shares of Sunesis Pharmaceuticals Inc. closed at $3.47 yesterday.

You May Also Be Interested In

• Goldman Sachs Downgrades AAC Technologies Holdings Inc. (2018:HK) (AACAY) to Neutral
• Kotak Upgrades Narayana Hrudayalaya Ltd (NARH:IN) to Buy (1)
• UBS Downgrades Converge ICT Solutions Inc (CNVRG:PM) to Neutral